



Commentary

Current status of terpenoids as inflammasome inhibitors

Sonsoles Hortelano^a, Laura González-Cofrade^b, Irene Cuadrado^b, Beatriz de las Heras^{b,*}^a *Unidad de Terapias Farmacológicas, Área de Genética Humana, Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Carretera de Majadahonda-Pozuelo Km 2, 28220 Madrid, Spain*^b *Departamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense de Madrid (UCM), Plaza Ramón y Cajal s/n, 28040 Madrid, Spain*

ARTICLE INFO

Keywords:

NLRP3-inflammasome

Terpenoids

Inflammation

ABSTRACT

Increasing evidence supports NLRP3 inflammasome as a new target to control inflammation. Dysregulation of NLRP3 inflammasome has been reported to be involved in the pathogenesis of several human inflammatory diseases. However, no NLRP3 inflammasome inhibitors are available in clinic. Terpenoids are natural products with multi-target activities against inflammation. Recent studies have revealed that these compounds are capable of inhibiting the activation of NLRP3 inflammasome in several mouse models of NLRP3 inflammasome-related pathogenesis. Thus, terpenoids represent an interesting pharmacological approach for the treatment of inflammatory diseases as they are endowed with a dual mechanism of inhibition of NF- κ B transcription factor and inflammasome activation, both critically involved in their anti-inflammatory effects. This work provides an overview of the current knowledge on the therapeutic potential of terpenoids as NLRP3 inflammasome inhibitors.

1. Introduction: overview of innate immune system and inflammation

Innate immune system is one of the first line of defense of the organism against infections and tissue injury. Its activation after recognition of pathogen associated molecular patterns (PAMPs) or danger-associated molecules patterns (DAMPs) initiates the inflammatory response leading to the recruitment of inflammatory cells and the release of pro-inflammatory mediators. Pattern recognition receptors (PRRs) localized on the cell membrane or intracellular space, are responsible for the recognition of invading pathogens or molecules from tissue injury [1]. Several families of PRRs have been described including the Toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs), retinoid acid-inducible gene I (RIG-I)-like receptors (RLRs), C-type lectin receptors (CLRs) and DNA sensors as absent in melanoma 2 (AIM2)-like receptors (ALRs), among others [2]. Whereas TLRs are mainly involved in PAMPs

detection; NLRs, RLRs and ALRs sense the presence of pathogens via PAMPs but are also endogenous sensors of tissue damage through DAMPs. Upon recognition of these signals, PRRs trigger different signaling pathways, leading to the activation of nuclear factor- κ B (NF- κ B), interferon regulatory factors (IRFs) or inflammasome formation [2]. A misbalance in this complex machinery may lead to a chronic inflammatory state contributing to the progression of several pathologies. Recent studies have suggested that NLR family and inflammasome complexes play crucial roles in the pathogenesis of several inflammatory diseases [1], being considered a new promising target for development of novel therapies. In this commentary, we summarize the available evidences about the inhibitory potential of natural products on inflammasome activity, focusing on terpenoids since they are a traditional source of anti-inflammatory compounds.

Abbreviations: ALRs, absent in melanoma 2 (AIM2)-like receptors; ASC, apoptosis-associated speck-like protein containing a CARD domain; CAPS, cryopyrin-associated periodic syndromes; CARD, caspase recruitment 'C' domain; CLRs, C-type lectin receptors; DAMPs, danger-associated molecules patterns; IFN, interferon; IL-1 β , interleukin-1 β ; IL-18, interleukin-18; LPS, lipopolysaccharide; LRRs, leucine-rich repeats; MSU, monosodium urate crystals; NACHT, nucleotide binding domain of NLRP3; NAIPs, NLR family apoptosis inhibitory proteins; NF- κ B, nuclear factor- κ B; NLRs, NOD-like receptors; NOD, nucleotide-binding oligomerization domain; PAMPs, pathogen associated molecular patterns; PRRs, pattern recognition receptors; PYD, pyrin 'P' domain; RLRs, retinoid acid-inducible gene I (RIG-I)-like receptors; ROS, reactive oxygen species; T2D, type 2 diabetes; T3SS, type III secretion system proteins; TLRs, toll-like receptors

* Corresponding author.

E-mail addresses: shortelano@isciii.es (S. Hortelano), lagonz11@ucm.es (L. González-Cofrade), icberrocal@ucm.es (I. Cuadrado), laseras@ucm.es (B. de las Heras).

<https://doi.org/10.1016/j.bcp.2019.113739>

Received 15 October 2019; Accepted 26 November 2019

Available online 28 November 2019

0006-2952/ © 2019 Elsevier Inc. All rights reserved.

2. PRRs and inflammasome

2.1. NOD-like receptors (NLRs)

NLRs are a large family of intracellular receptors that participate in the recognition of pathogens and molecules from damaged cells to regulate the inflammatory response. They are mainly expressed in inflammatory cell types such as macrophages, neutrophils or dendritic cells [3,4]. Members of the NLR family are structurally tri-domain proteins formed by an N-terminal protein-protein interaction domain such as caspase recruitment 'C' (CARD) or pyrin 'P' (PYD) domains, a central NOD and a C-terminal leucine-rich repeats (LRRs) [5]. These domains exhibit different functions, thus, LRRs are essential for auto-regulation and detention of PAMPs and DAMPs, leading to NLR activation; NOD region exerts regulatory and oligomerization functions and CARD and PYD domains have a signaling function through protein-protein interactions with downstream factors [5]. Over 22 NLR members have been described with important functions in signal transduction and inflammatory responses. Thus, some of those NLR family members such as NLRP1, NLRP3 and NLRC4 can form multiprotein complexes, called inflammasomes, leading to caspase-1 activation and subsequently secretion of pro-inflammatory cytokines interleukin-1 β (IL-1 β) and interleukin-18 (IL-18) [6,7].

2.2. ALR family

ALRs are a class of PRRs which recognizes cytosolic and nuclear pathogen DNA [8]. Members of this family include AIM2 and the interferon (IFN)-inducible protein 16 (IFI16) which act as dsDNA sensors activating inflammasome. ALRs are characterized by an N-terminal Pyrin signaling domain (PYD) and a C-terminal DNA-binding hemato-poietic interferon (IFN)-inducible nuclear protein with a 200-amino-acid repeat (HIN200) domain. PYD domain mediates protein-protein bindings and interacts with an apoptosis-associated speck-like protein containing a CARD domain (ASC), whereas the HIN domain is responsible for dsDNA recognition [9]. Correct binding and oligomerization require longer stretches of dsDNA, since both receptors lack from an ATP-dependent oligomerization NOD domain similar to that exhibited by members of the NLR family [10].

3. Inflammasome

Inflammasomes are multiprotein complexes who play an essential role in the innate immune system, eliciting a defense response against pathogens and damaged cells [11]. Their structure consists in a sensor protein (a NLR, such as NLRP1, NLRP3 and NLRC4 or a ALR as AIM2), which recognizes PAMPs and DAMPs; an adaptor protein ASC, which acts as a bridge between NLRs/AIM2 and pro-caspase-1; and an effector molecule (precursor of caspase-1) [12]. Upon recognition of PAMPs and DAMPs by NLRs/AIM2, ASC is recruited to the complex via a pyrin-pyrin domain interaction, forming a very large supramolecular structure called pyroptosome. Complete inflammasome formation requires binding of pro-caspase-1 to ASC through CARD-CARD domains [13]. Inflammasome formation results in autocatalytic cleavage of pro-caspase-1 to form enzymatically active caspase-1. Activated caspase-1 leads to the maturation and secretion of pro-inflammatory cytokines IL-1 β and IL-18 [14] or to the cleavage of gasdermin D protein which forms membrane pores to trigger pyroptosis, a class of programmed necrotic cell death [15,16].

To date, five inflammasome complexes have been well established: NLRP1, NLRP3, NLRC4, AIM2, and the recently discovered Pyrin inflammasomes [17].

NLRP1, the first reported inflammasome, acts as a sensor for anthrax lethal toxin activity or *Toxoplasma gondii* infection [7]. It consists of a N-terminal PYD domain, a NOD domain followed by LRRs, a functional-to-find (FIIND) domain, and a C-terminal CARD domain.

Since it contains both PYD and CARD domains, caspase-1 activation has been described in the absence of ASC through direct interaction between CARD motifs of NLRP1 and pro-caspase-1 [18].

NLRP3 inflammasome is the best studied and characterized of the inflammasomes. Importantly, NLRP3 inflammasome complex activation has been shown to involve a two-step process: a first signal or "priming", mediated through PAMPs, such as lipopolysaccharide (LPS) recognized by TLRs that lead to NF- κ B translocation into the nucleus, thus inducing inflammasome components NLRP3, pro-IL-1 β and pro-IL-18 expression; and a second signal specific to the inflammasome. This can be triggered by many and diverse stimuli including bacteria pore-forming toxins, viruses, fungi, protozoa, reactive oxygen species (ROS) and non-microbial signals such as monosodium urate (MSU) crystals or particulate matter as asbestos and silica, making NLRP3 the most versatile inflammasome [18–20].

Common molecular and cellular events must be responsible for the activation and assembly of the NLRP3 inflammasome, including K⁺ efflux, Ca⁺² mobilization, lysosomal rupture, ROS production and mitochondrial dysfunction. These mechanisms lead to the formation of the complex NLRP3, ASC, and pro-caspase-1. ASC is essential for interaction with pro-caspase-1 as NLRP3 has no a CARD domain. NLRP3 interacts with ASC through their PYD motifs and ASC with pro-caspase 1 via their CARD motifs. Besides, ATPase activity of NLRP3 is critical for the oligomerization of NLRP3 and its consequent activation [21].

NLRC4 is also an important sensor for inflammasome formation upon recognition of specific bacterial proteins, such as flagellin or type III secretion system proteins (T3SS) [22]. Among NLRs, NLRC4 exhibits special characteristics since it requires additional sensors, the NLR family apoptosis inhibitory proteins (NAIPs), that acts as cytosolic receptors for flagellin and T3SS [23]. Thus, members of this family as NAIP1 and NAIP2 interact with components of T3SS whereas NAIP5 and NAIP6 recognize flagellin. Upon ligand binding, NAIPs recruit and co-oligomerize with NLRC4, and the resulting NAIP/NLRC4 inflammasome can activate caspase-1 [22,23]. This activation may be mediated by ASC leading to IL-1 β and IL-18 production and results in pyroptosis whether NLRC4 activates itself caspase-1 [24].

AIM2 has been described as the sensor for cytosolic dsDNA of several pathogens including cytomegalovirus, *Francisella tularensis* and vaccinia virus [25]. AIM2 is a member of the IFN-inducible Pyrin and HIN domain (PYHIN) proteins that contain a C-terminal HIN-200 domain and an N-terminal PYD domain [26]. HIN200 domain binds dsDNA and PYD-PYD interactions result on ASC recruitment and caspase-1 activation.

Pyrin inflammasome is not a direct sensor of PAMPs but a detector of covalent modifications of Rho family proteins induced by bacterial toxins [27]. Pyrin contains an N-terminal PYD domain that interacts with ASC and subsequently stimulate caspase-1 activation leading to IL-1 β and IL-18 production [28].

4. Inflammasomes in inflammatory diseases

Despite the enormous importance of inflammasomes in the physiological modulation of innate immune response, numerous evidences have demonstrated that inflammasome dysregulation is linked to a variety of inflammatory diseases. Thus, aberrant inflammasome activation resulting in excessive secretion of interleukins and induction of inflammatory cell death has been associated with the pathogenesis of cardiovascular disease as atherosclerosis, diabetes, neurological disorders as Alzheimer and Parkinson's disease, gout, a group of rare autoinflammatory diseases named as cryopyrin-associated periodic syndromes (CAPS), kidney diseases, colitis, arthritis and psoriasis, among others [29–34].

Single nucleotide polymorphisms (SNPs) in the promoter and coding regions of NLRP1 have been linked to vitiligo, Addison's disease, and type I diabetes [29]. These mutations were related to conformational changes in NLRP1 resulting in an excessive production of the pro-




Fig. 1. Chemical structures of terpenoids influencing NLRP3-inflammasome activation.

inflammatory cytokines IL-1 β and IL-18. Furthermore, NLRP1 upregulation in response to amyloid- β aggregates has been observed in Alzheimer's disease, producing caspase-1 activation and subsequent neuronal cell death [35].

Gain-of-function mutations in NLRP3 are associated with a group of rare autoinflammatory diseases known as CAPS, characterized by urticarial skin rashes and recurrent fever and inflammation. These fever syndromes included familial cold autoinflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurological cutaneous and articular syndrome/neonatal onset multisystem inflammatory disease (CINCA/NOMID), ranging from the most mild to the most severe, respectively [29]. Similarly to NLRP1 mutations, NLRP3 changes also results in continuous caspase-1 activation leading to an excessive secretion of IL-1 β production [36]. Opposite, an increased susceptibility to Crohn's disease has been associated with a reduced IL-1 β production due to a defective NLRP3 expression [37]. Interestingly, contradictory evidences about the role of NLRP3 have been reported in ulcerative colitis, another inflammatory bowel disease (IBD). Thus, detrimental or protective effects have been described for NLRP3 in this pathology mainly dependent on differences in the composition of the microbiota or genetic background [38]. Additionally, recent evidences demonstrate that NLRP3 inflammasome is involved on atherosclerosis development or gout as cholesterol or MSU crystals act as inflammasome sensors [39,40].

In the same line as the previously reported NLRP1 and NLRP3 mutations, defects on NLRP4 resulting in a hyperactivation of inflammasome are related with spontaneous autoinflammatory symptoms resulting in pathologies as syndrome of enterocolitis, macrophage activation syndrome (MAS) or atopic dermatitis [41–44].

Regarding AIM2 inflammasome, its ability to recognize its self-DNA contributes to the development of various autoimmune and autoinflammatory diseases including psoriasis, arthritis, systemic lupus erythematosus, dermatitis and abdominal aortic aneurysm [45–48].

Finally, few data are still available about the role of pyrin inflammasome as cause of pathologies, although associations with some monogenic autoinflammatory syndromes have been described including familial Mediterranean fever (FMF) or pyrin-associated autoinflammation with neutrophilic dermatosis (PAAND) [49,50].

5. Natural compounds

Natural products and their derivatives represent a successful source in drug discovery and development of new therapeutic agents. Terpenoids, a large and structurally diverse group of natural products, are bioactive compounds widely distributed in nature. The first step of terpenoids biosynthesis is the generation of a C₅ unit like as isopentenyl diphosphate (IPP) or dimethylallyl diphosphate (DMAPP) that are generated by two distinct biosynthetic pathways: the mevalonate (MVA) and the methylerythritol-phosphate (MEP) pathway. On the basis of C₅ units, terpenoids are classified as C₅ (hemiterpenes), C₁₀ (monoterpenes), C₁₅ (sesquiterpenes), C₂₀ (diterpenes), C₂₅ (sesterpenes), C₃₀ (triterpenes), and C₄₀ (tetraterpenes) [51].

Terpenoids are endowed with a wide range of biological activities as

antimicrobial, antiviral, anti-tumoral, antioxidant, antimalarial and cardioprotective agents, among others [52–57]. In addition, they have shown to exhibit potent anti-inflammatory and immunomodulatory properties in multiple inflammatory disorders [58–63]. Interestingly, these compounds have gained attention since they can act on specific and/or multiple molecular and cellular targets.

The great anti-inflammatory potential of these compounds has been largely associated to inhibition of classical inflammatory signaling pathways, as the activation of the NF- κ B transcription factor and Mitogen-activated protein kinases (MAPKs) in various experimental disease models [60,64,65].

In recent years, inflammasome has emerged as a new therapeutic target in different inflammatory driven human diseases [29]. So far, one of the best studied inflammasomes is NLRP3. In the search of drugs targeting the inflammasome, several terpenoids have been evaluated against NLRP3 inflammasome complex (Fig. 1). Accordingly, this work highlights and critically examines the current knowledge about terpenoids as potential NLRP3 inflammasome inhibitors (Table 1).

The first natural product found to inhibit inflammasome activity via direct targeting of caspase-1 and NLRP3 was parthenolide, a sesquiterpene lactone isolated from *Tanacetum parthenium* L. (Asteraceae) (feverfew) [66]. Since then, several terpenoids have demonstrated to exert inhibitory effects on this pathway.

Triptolide

Triptolide was isolated from the Chinese herb *Tripterygium wilfordii* Hook F (Celastraceae). Both *in vitro* and *in vivo* antifibrotic effects of this diterpene were reported in a mouse model of cardiac fibrosis [67]. Experiments revealed its molecular mechanism with insights into the NLRP3 inflammasome pathway, through a dual role, by downregulating the expression of NLRP3 inflammasome components as NLRP3 and ASC, and by interrupting NLRP3 inflammasome assembly. Triptolide also demonstrated therapeutic effects in a mouse model of myocardial remodeling induced by chronic pressure overload by decreasing cytokine (IL-1 β , IL-18) serum levels and downregulating the profibrotic transforming growth factor- β 1 (TGF- β 1) activation [68]. In the same context of inhibition of inflammasome-mediated pro-inflammatory cytokines production, downregulation of NLRP3 and TLR4 expression with improvement of functional renal parameters by triptolide was observed in a rat kidney injury model [69].

Oridonin

Oridonin, an *ent*-kaurane diterpene, is the major active constituent from *Rabdosia rubescens* (Hemsl.) Hara (Lamiaceae). He *et al.* (2018) demonstrated that oridonin is a specific covalent inhibitor of NLRP3 inflammasome assembly and activation [70]. It acts as a Michael receptor thanks to the α,β -unsaturated carbonyl unit and covalently binds to Cys279 of NACHT domain of NLRP3 to block the interaction between NLRP3 and NEK7, a critical step for the subsequent NLRP3 oligomerization and recruitment of ASC. Dose-dependent inhibitory effects on caspase-1 cleavage, IL-1 β secretion, and cell death

Table 1
Terpenoids inhibiting NLRP3 inflammasome activation in experimental models.

Terpenoid	Molecular mechanism	Experimental models	References
Triptolide	Interruption of NLRP3-ASC assembly and suppression TLR4 expression	Cardiac fibrosis Myocardial remodeling Kidney injury	[67], [68], [69]
Oridonin	Block the interaction between NLRP3 and NEK-7	MSU-induced peritonitis and gouty arthritis Type 2 diabetes (T2D) LPS-induced acute lung injury	[70], [71]
Andrographolide	Disruption of NLRP3-PYCARD-caspase-1 complex assembly and reduction in the expression of inflammasome components through NF- κ B inhibition	Nonalcoholic steatohepatitis (NASH) Lung injury Colitis-associated cancer (CAC)	[72], [73], [74]
Celastrol	Block ASC oligomerization and NLRP3 complex formation, autophagy, NF κ B-signaling pathway and ROS production	Dextran sodium sulfate(DSS)-induced colitis LPS-induced septic shock	[76], [77], [78], [79]
Genipin	Inhibition of NLRP3-mediated ASC oligomerization, autophagy signaling pathway and ROS production	LPS- and aluminium-induced peritonitis Flagellin-induced lung inflammation D-galactosamine and LPS-induced hepatic injury	[80], [81], [82]

after stimulation by different NLRP3 agonists [nigericin, MSU, ATP or cytosolic LPS (cLPS)] have been shown. Furthermore, this study also demonstrated that oridonin suppressed NLRP3-dependent inflammation in mouse models of chronic inflammatory diseases such as peritonitis, gouty arthritis and type 2 diabetes (T2D) [70]. Additionally, oridonin exerted protective effects in a model of LPS-induced acute lung injury by downregulation of the expression of NLRP3-inflammasome components and inhibition of NF- κ B pathway. Interestingly, oridonin protective effects in lung injury were due not only for its anti-inflammatory activity but also for its nuclear factor erythroid-2 (Nrf2)-dependent antioxidant activity [71].

Andrographolide

Andrographolide is a labdane diterpenoid from *Andrographis paniculata* (Burm.f.) Nees (Acanthaceae). Inhibitory effects of andrographolide on NLRP3 inflammasome activation in experimental non-alcoholic steatohepatitis, lung injury, and colitis-associated cancer have been reported [72–74]. In these models, inhibitory effects of andrographolide have been related to the disruption of the NLRP3-caspase-1 assembly, thereby inhibiting caspase-1 activation and leading to a decrease in the IL-1 β secretion. Interestingly, in nonalcoholic steatohepatitis, andrographolide's modulatory effect was also mediated by a NF- κ B-dependent mechanism [72]. Finally, similar mechanisms have been described in intracerebral hemorrhage (ICH)-induced secondary brain injury (SBI) [75]. Andrographolide reduced neuroinflammation via blocking the assembly of the NLRP3/ASC/caspase-1 together with the inhibition of pyroptosis.

Celastrol

The triterpenoid celastrol is the most promising bioactive compound isolated from *Tripterygium wilfordii* Hook F (Celastraceae). Protective effects of celastrol in a model of LPS-induced septic shock and dextran sulfate sodium (DSS)-induced colitis, identified this compound as a NLRP3 inhibitor [76,77]. Interruption of ASC oligomerization and autophagy activation by the triterpenoid were the main mechanisms involved, leading to the inhibition of caspase-1 activation and IL-1 β and IL-18 release. Of note, this compound has been reported to inhibit NLRP3 inflammasome activation by reducing both the priming and activating signals. Thus, celastrol suppressed pyroptosis and reduced the secretion of IL-1 β and IL-18 by inhibiting the expression of NLRP3 and the cleavage of caspase-1 in response to LPS/ATP induction, but also inhibited the NF- κ B pathway and ROS production acting as a dual inhibitor [78,79].

In contrast to the previous terpenoids, **genipin**, an iridoid monoterpenoid isolated from *Gardenia jasminoides* Ellis (Rubiaceae) fruits has been reported to inhibit not only NLRP3 but also NLRP4 inflammasome activation. Preincubation of macrophages with genipin specifically inhibited IL-1 β secretion and caspase-1 cleavage, without affecting tumor necrosis factor- α (TNF- α), pro-IL-1 β , pro-caspase-1 and ASC levels. Genipin prevented ASC-complex formation, but not NLRP4-mediated ASC oligomerization, suggesting that the compound may affect upstream signaling. In fact, it was demonstrated that genipin inhibited the autophagy signaling pathway and ROS production acting at the mitochondrial uncoupling protein-2 (UCP2) level, which leads to NLRP3 and NLRP4 inflammasome suppression [80,81]. These results were confirmed *in vivo* in models of peritonitis, lung inflammation and hepatic injury [80,82].

Collectively, these findings identify NLRP3 inflammasome activation as a critical target involved in the anti-inflammatory mechanism of these terpenoids, suggesting the role of these natural products as promising therapeutic agents in various inflammatory diseases (Fig. 2). In addition, the well-known inhibitory effect of some of these compounds on NF- κ B activation opens new strategies to develop dual inhibitors which can simultaneously suppress both inflammasome activation and NF- κ B-dependent activation.

6. Other non-natural compounds as inhibitors

In addition to terpenoids, several small molecules have been identified as specific pharmacological inhibitors to NLRP3 inflammasome [83] (Table 2).

The vinyl sulfone **BAY 11-7082**, selectively inhibited activation of the NLRP3 inflammasome targeting its ATPase activity in an irreversible way. BAY 11-7082 showed to inhibit NLRP3-induced ASC pyroptosome formation and pyroptotic cell death in macrophages [66] and in a mouse model of psoriasis-like dermatitis [84].

MCC950, a diarylsulfonylurea-containing compound, impaired the activation of caspase-1 by NLRP3 and IL-1 β release in both mouse and human macrophages, without altering pro-caspase-1, pro-IL-1 β or ASC expression [85]. It blocked NLRP3 induced ASC oligomerization, but it did not prevent NLRP3-NLRP3 or NLRP3-ASC interactions. MCC950 specifically blocked NLRP3-dependent pyroptotic cell death, but had no effect on potassium efflux or calcium flux. MCC950 showed to reduced IL-1 β and IL-18 levels *in vivo*, attenuating the severity of autoimmune encephalomyelitis, ulcerative colitis and CAPS disease models [85,86]. Interestingly, new insights into the mechanism of action of MCC950 have shown that this molecule induces conformational changes on NLRP3, leading to an inactive state [87].




Fig. 2. Signaling pathways involved in modulation of NLRP3 inflammasome activation by terpenoids. Two signals are required to activate NLRP3 inflammasome: the signal 1 or “priming”, where TLRs sense PAMPs such as LPS leading to NFκB activation and translocation into the nucleus, thus inducing the transcription of pro-IL-1β, pro-IL-18 and inflammasome components; the signal 2 or activation, which can be triggered by many diverse stimuli (ATP, Nigericin, ROS) and involves molecular and cellular events such as K⁺ efflux and lysosomal damage resulting in the assembly and oligomerization of the NLRP3 inflammasome complex. Then, caspase-1 activation induce the maturation and release of the pro-inflammatory cytokines IL-1β and IL-18. Terpenoids are potent inhibitors of NLRP3-inflammasome-mediated IL-1β production, acting at more than one element of the involved pathways.

Tranilast is an analog of a tryptophan metabolite which has been traditionally used as an anti-allergic drug. Tranilast directly binds to NLRP3 and suppresses its oligomerization blocking NLRP3-NLRP3 interaction in an ATPase-independent manner, so no effects on the upstream events potassium efflux, mitochondrial damage or chloride efflux are detected. Inhibition of inflammasome activation is involved in the anti-inflammatory effects of tranilast on mouse models of gouty arthritis, CAPS diseases, and T2D [88].

In contrast to tranilast, **CY-09**, a thiazolidinone analog, directly binds to the ATP-binding motif of NLRP3 NACHT domain and inhibits NLRP3 ATPase activity, resulting in the suppression of NLRP3 inflammasome assembly and activation. Beneficial effects in mice models of T2D and CAPS, as well as *ex vivo* in monocytes from patients with gout were reported [89].

Finally, an orally β-sulfonyl nitrile molecule called **OLT1177** or **dapansutrile**, has also been recently described to prevent NLRP3-ASC

Table 2
Non-natural compounds inhibiting NLRP3 inflammasome activation in experimental models.

Compound	Molecular mechanism	Experimental models	References
BAY 11-7082 MCC950	Disruption of NLRP3 ATPase activity and the ASC pyroptosome formation Block ASC oligomerization and induction of conformational changes on NLRP3	Imiquimod (IMQ)-induced psoriasis Encephalomyelitis Colitis	[66], [84] [85], [86], [87]
Tranilast	Block NLRP3 oligomerization in an ATPase-independent manner	Cryopyrin-associated periodic syndrome (CAPS) Gouty arthritis	[88]
CY-09	Inhibition of NLRP3-ATPase activity	Cryopyrin-associated periodic syndrome (CAPS) Type 2 Diabetes (T2D)	[89]
OLT1177 or dapansutrile	Prevention of NLRP3-ASC and NLRP3-caspase-1 interactions	Cryopyrin-associated periodic syndrome (CAPS) LPS-induced systemic inflammation Gouty arthritis	[90], [91]

and NLRP3-caspase-1 interactions, blocking inflammasome oligomerization in macrophages. Potassium efflux and gene expression of pro-IL-1 β were not affected by OLT1177. These effects were confirmed *ex vivo* in neutrophils and monocytes isolated from patients with CAPS and *in vivo* reducing the severity of LPS-induced systemic inflammation in mice [90]. Treatment with OLT1177 also reduced joint inflammation in reactive and gouty mouse arthritis, with a significant decrease of IL-1 β and IL-6 secretion [91]. These results together with its favorable phase I safety profile, encouraged to the evaluation of oral treatment with OLT1177 in phase II clinical trials.

7. Conclusion and future directions

Inflammation has long been identified as a critical factor of many inflammatory conditions and autoimmunity. In recent years, significant progress has been made to understand the inflammasomes, specifically NLRP3, its regulation and role in diverse human diseases. Although inhibition of the NLRP3 inflammasome reduces inflammation in murine models of acute and chronic inflammatory diseases, there is currently no approved inflammasome inhibitor for human use.

A few compounds have been reported to possess potential inhibitory effects on NLRP3 inflammasome activation. Emerging evidence in the literature have revealed that some natural products, in particular terpenoids are capable of inhibiting the activation of NLRP3 inflammasome to modulate inflammatory disease pathogenicity, as detailed in this commentary. The summarized studies revealed that terpenoids regulates the NLRP3 inflammasome with beneficial effects in several experimental models of chronic inflammation-associated diseases (colitis, CAPS, gouty arthritis...).

In addition, terpenoids have long been identified as potent inhibitors of the transcription factor NF- κ B, a pivotal regulator for gene transcription of pro-inflammatory cytokines and chemokines implicated in numerous immune and chronic inflammatory disorders. To date, commercially available anti-inflammatory agents are potent inhibitors of cytokine production in these pathologies by interrupting NF- κ B signaling pathway. Interestingly, NF- κ B is also a first signal in NLRP3 inflammasome activation, being the responsible of the inflammasome components synthesis, so targeting this pathway may also result in decreased levels of IL-1 β .

Although many challenges remain for elucidating the exact mechanisms by which terpenoids regulate the activation of NLRP3 inflammasome complex, recent studies suggest that terpenoids represent an interesting pharmacological approach as anti-inflammatory agents. The combined inhibitory effects of these compounds on both TLR4-NF- κ B pathway and NLRP3 inflammasome activation process may render terpenoids as very promising candidates for the development of safe and efficacious novel therapeutics for the management of NLRP3-inflammatory diseases.

Author contributions

SH, LG and IC, contributed to the writing of the manuscript. LG and IC also participated actively in the design of Tables and Figures, and drawing of chemical structures. BH, the corresponding author, contributed in the conception, design and writing of the manuscript submitted. All authors read and approved the final manuscript for submission to Biochemical Pharmacology.

Funding

This work was supported by grant PI11/00036, PI14/00055, and PI17/00012 from the FIS, MPY 1410/09 from ISCIII and Spanish Ministry of Health (Instituto de Salud Carlos III; RD12/0036/0059) to SH and grant RTI2018-094356-B-C21 from Ministerio de Economía y Competitividad to LGC, IC and BH. LGC received a predoctoral fellowship award from the Spanish Ministry of Education, Culture and

Sports (FPU17/03519).

References

- [1] F. Martinon, A. Mayor, J. Tschopp, The inflammasomes: guardians of the body, *Annu. Rev. Immunol.* 27 (2009) 229–265.
- [2] S. Akira, S. Uematsu, O. Takeuchi, Pathogen recognition and innate immunity, *Cell* 124 (4) (2006) 783–801.
- [3] K. Newton, V.M. Dixit, Signaling in innate immunity and inflammation, *Cold Spring Harb. Perspect. Biol.* 4 (3) (2012) a006049.
- [4] O. Takeuchi, S. Akira, Pattern recognition receptors and inflammation, *Cell* 140 (6) (2010) 805–820.
- [5] K. Schroder, J. Tschopp, The inflammasomes, *Cell* 140 (6) (2010) 821–832.
- [6] J.H.F. Pedra, S.L. Cassel, F.S. Sutterwala, Sensing pathogens and danger signals by the inflammasome, *Curr. Opin. Immunol.* 21 (1) (2009) 10–16.
- [7] F. Martinon, K. Burns, J. Tschopp, The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta, *Mol. Cell* 10 (2) (2002) 417–426.
- [8] V. Caneparo, S. Landolfo, M. Gariglio, M. De Andrea, The absent in melanoma 2-like receptor IFN-inducible protein 16 as an inflammasome regulator in systemic lupus erythematosus: the dark side of sensing microbes, *Front. Immunol.* 9 (2018) 1180 1180.
- [9] N. Shaw, Z.-J. Liu, Role of the HIN domain in regulation of innate immune responses, *Mol. Cell. Biol.* 34 (1) (2014) 2–15.
- [10] T.S. Xiao, The nucleic acid-sensing inflammasomes, *Immunol. Rev.* 265 (1) (2015) 103–111.
- [11] D. Sharma, T.-D. Kanneganti, The cell biology of inflammasomes: mechanisms of inflammasome activation and regulation, *J. Cell Biol.* 213 (6) (2016) 617–629.
- [12] H. Guo, J.B. Callaway, J.P.Y. Ting, Inflammasomes: mechanism of action, role in disease, and therapeutics, *Nat. Med.* 21 (7) (2015) 677–687.
- [13] T.A. Kufer, P.J. Sansonetti, NLR functions beyond pathogen recognition, *Nat. Immunol.* 12 (2) (2011) 121–128.
- [14] B.K. Davis, H. Wen, J.P.Y. Ting, The inflammasome NLRs in immunity, inflammation, and associated diseases, *Annu. Rev. Immunol.* (2011) 707–735.
- [15] J. Shi, W. Gao, F. Shao, Pyroptosis: gasdermin-mediated programmed necrotic cell death, *Trends Biochem. Sci.* 42 (4) (2017) 245–254.
- [16] E. Latz, T.S. Xiao, A. Stutz, Activation and regulation of the inflammasomes, *Nat. Rev. Immunol.* 13 (6) (2013) 397–411.
- [17] T.-D. Kanneganti, The inflammasome: firing up innate immunity, *Immunol. Rev.* 265 (1) (2015) 1–5.
- [18] L. Franchi, N. Warner, K. Viani, G. Nuñez, Function of Nod-like receptors in microbial recognition and host defense, *Immunol. Rev.* 227 (1) (2009) 106–128.
- [19] A. Abderrazak, T. Syrovets, D. Couchie, K. El Hadri, B. Friguet, T. Simmet, M. Rouis, NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases, *Redox Biol.* 4 (2015) 296–307.
- [20] M. Yabal, D.J. Calleja, D.S. Simpson, K.E. Lawlor, Stressing out the mitochondria: Mechanistic insights into NLRP3 inflammasome activation, *J. Leukoc. Biol.* 105 (2) (2019) 377–399.
- [21] J.A. Duncan, D.T. Bergstralh, Y. Wang, S.B. Willingham, Z. Ye, A.G. Zimmermann, J.P. Ting, Cryopyrin/NALP3 binds ATP/dATP, is an ATPase, and requires ATP binding to mediate inflammatory signaling, *Proc. Natl. Acad. Sci. U.S.A.* 104 (19) (2007) 8041–8046.
- [22] E.A. Miao, D.P. Mao, N. Yudkovsky, R. Bonneau, C.G. Lorang, S.E. Warren, I.A. Leaf, A. Aderem, Innate immune detection of the type III secretion apparatus through the NLRP4 inflammasome, *Proc. Natl. Acad. Sci. U.S.A.* 107 (7) (2010) 3076–3080.
- [23] J. von Moltke, J.S. Ayres, E.M. Kofoed, J. Chavarria-Smith, R.E. Vance, Recognition of bacteria by inflammasomes, *Annu. Rev. Immunol.* 31 (2013) 73–106.
- [24] E.A. Miao, I.A. Leaf, P.M. Treuting, D.P. Mao, M. Dors, A. Sarkar, S.E. Warren, M.D. Wewers, A. Aderem, Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria, *Nat. Immunol.* 11 (12) (2010) 1136–1142.
- [25] J. Lugrin, F. Martinon, The AIM2 inflammasome: Sensor of pathogens and cellular perturbations, *Immunol. Rev.* 281 (1) (2018) 99–114.
- [26] L.E. Ludlow, R.W. Johnstone, C.J. Clarke, The HIN-200 family: more than interferon-inducible genes? *Exp. Cell Res.* 308 (1) (2005) 1–17.
- [27] O. Schnappauf, J.J. Chae, D.L. Kastner, I. Aksentijevich, The Pyrin Inflammasome in Health and Disease, *Front. Immunol.* 10 (1745) (2019).
- [28] C. de Torre-Minguela, P. Mesa del Castillo, P. Pelegrín, The NLRP3 and Pyrin Inflammasomes: Implications in the Pathophysiology of Autoinflammatory Diseases, *Front. Immunol.* 8 (43) (2017).
- [29] M. Lamkanfi, L. Vande Walle, T.-D. Kanneganti, Deregulated inflammasome signaling in disease, *Immunol. Rev.* 243 (1) (2011) 163–173.
- [30] D. De Nardo, E. Latz, NLRP3 inflammasomes link inflammation and metabolic disease, *Trends Immunol.* 32 (8) (2011) 373–379.
- [31] N. An, Y. Gao, Z. Si, H. Zhang, L. Wang, C. Tian, M. Yuan, X. Yang, X. Li, H. Shang, X. Xiong, Y. Xing, Regulatory mechanisms of the NLRP3 inflammasome, a novel immune-inflammatory marker in cardiovascular diseases, *Front. Immunol.* 10 (2019) 1592 1592.
- [32] J. Fan, K. Xie, L. Wang, N. Zheng, X. Yu, Roles of inflammasomes in inflammatory kidney diseases, *Mediators Inflamm.* 2019 (2019) 2923072-2923072.
- [33] A.K. So, F. Martinon, Inflammation in gout: mechanisms and therapeutic targets, *Nat. Rev. Rheumatol.* 13 (11) (2017) 639–647.
- [34] F. Su, Y. Xia, M. Huang, L. Zhang, L. Chen, Expression of NLRP3 in psoriasis is associated with enhancement of interleukin-1beta and caspase-1, *Med. Sci. Monit.* 24 (2018) 7909–7913.

- [35] J.K.Y. Yap, B.S. Pickard, E.W.L. Chan, S.Y. Gan, The role of neuronal NLRP1 inflammasome in Alzheimer's disease: bringing neurons into the neuroinflammation game, *Mol. Neurobiol.* (2019), <https://doi.org/10.1007/s12035-019-1638-7>.
- [36] L. Agostini, F. Martinon, K. Burns, M.F. McDermott, P.N. Hawkins, J. Tschopp, NALP3 forms an IL-1 β -processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder, *Immunity* 20 (3) (2004) 319–325.
- [37] A.-C. Villani, M. Lemire, G. Fortin, E. Louis, M.S. Silverberg, C. Collette, N. Baba, C. Libioulle, J. Belaiche, A. Bitton, D. Gaudet, A. Cohen, D. Langelier, P.R. Fortin, J.E. Wither, M. Sarfati, P. Rutgeerts, J.D. Rioux, S. Vermeire, T.J. Hudson, D. Franchimont, Common variants in the NLRP3 region contribute to Crohn's disease susceptibility, *Nat. Genet.* 41 (1) (2009) 71–76.
- [38] Y. Zhen, H. Zhang, NLRP3 inflammasome and inflammatory bowel disease, *Front. Immunol.* 10 (2019) 276–276.
- [39] P. Duewell, H. Kono, K.J. Rayner, C.M. Sirois, G. Vladimer, F.G. Bauernfeind, G.S. Abela, L. Franchi, G. Nuñez, M. Schnurr, T. Espevik, E. Lien, K.A. Fitzgerald, K.L. Rock, K.J. Moore, S.D. Wright, V. Hornung, E. Latz, NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, *Nature* 464 (2010) 1357.
- [40] F. Martinon, V. Petrilli, A. Mayor, A. Tardivel, J. Tschopp, Gout-associated uric acid crystals activate the NALP3 inflammasome, *Nature* 440 (7081) (2006) 237–241.
- [41] A. Kitamura, Y. Sasaki, T. Abe, H. Kano, K. Yasutomo, An inherited mutation in NLRCA4 causes autoinflammation in human and mice, *J. Exp. Med.* 211 (12) (2014) 2385–2396.
- [42] S.W. Canna, A.A. de Jesus, S. Gouni, S.R. Brooks, B. Marrero, Y. Liu, M.A. DiMattia, K.J.M. Zaal, G.A.M. Sanchez, H. Kim, D. Chapelle, N. Plass, Y. Huang, A.V. Villarinio, A. Biancotto, T.A. Fleisher, J.A. Duncan, J.J. O'Shea, S. Benseler, A. Grom, Z. Deng, R.M. Laxer, R. Goldbach-Mansky, An activating NLRCA4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome, *Nat. Genet.* 46 (10) (2014) 1140–1146.
- [43] N. Romberg, K. Al Moussawi, C. Nelson-Williams, A.L. Stiegler, E. Loring, M. Choi, J. Overton, E. Meffre, M.K. Khokha, A.J. Huttner, B. West, N.A. Podoltssev, T.J. Boggon, B.I. Kazmierczak, R.P. Lifton, Mutation of NLRCA4 causes a syndrome of enterocolitis and autoinflammation, *Nat. Genet.* 46 (10) (2014) 1135–1139.
- [44] F. Macaluso, M. Nothnagel, Q. Parvez, E. Petrasch-Parwez, F.G. Bechara, J.T. Epplein, S. Hoffjan, Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis, *Exp. Dermatol.* 16 (8) (2007) 692–698.
- [45] Y. Dombrowski, M. Peric, S. Koglin, C. Kammerbauer, C. Goss, D. Anz, M. Simanski, R. Glaser, J. Harder, V. Hornung, R.L. Gallo, T. Ruzicka, R. Besch, J. Schaubert, Cytosolic DNA triggers inflammasome activation in keratinocytes in psoriatic lesions, *Sci. Transl. Med.* 3 (82) (2011) 82ra38.
- [46] D. Choubey, Interferon-inducible Iff200-family genes as modifiers of lupus susceptibility, *Immunol. Lett.* 147 (1–2) (2012) 10–17.
- [47] S. Dihlmann, P. Erhart, A. Mehrabi, A. Nickholgh, F. Lasitschka, D. Bockler, M. Hakimi, Increased expression and activation of absent in melanoma 2 inflammasome components in lymphocytic infiltrates of abdominal aortic aneurysms, *Mol. Med.* 20 (2014) 230–237.
- [48] B.R. Sharma, R. Karki, T.-D. Kanneganti, Role of AIM2 inflammasome in inflammatory diseases, cancer and infection, *Eur. J. Immunol.* (2019) 1–14.
- [49] J. Yang, H. Xu, F. Shao, Immunological function of familial Mediterranean fever disease protein Pyrin, *Sci. China Life Sci.* 57 (12) (2014) 1156–1161.
- [50] Y. Jamilloux, F. Magnotti, A. Belot, T. Henry, The pyrin inflammasome: from sensing RhoA GTPases-inhibiting toxins to triggering autoinflammatory syndromes, *Pathog. Dis.* 76 (3) (2018).
- [51] P.M. Dewick, The mevalonate and deoxyxylulose phosphate pathway. In: *Medicinal Natural Products: a biosynthetic approach*, John Wiley and Sons, Chichester, 2002, 2nd ed., 167–232.
- [52] I. Cuadrado-Berrocal, M.V. Gomez-Gavero, Y. Benito, A. Barrio, J. Bermejo, M.E. Fernandez-Santos, P.L. Sanchez, M. Desco, F. Fernandez-Aviles, M. Fernandez-Velasco, L. Bosca, B. de Las Heras, A labdane diterpene exerts ex vivo and in vivo cardioprotection against post-ischemic injury: involvement of AKT-dependent mechanisms, *Biochem. Pharmacol.* 93 (4) (2015) 428–439.
- [53] B. Singh, R.A. Sharma, Plant terpenes: defense responses, phylogenetic analysis, regulation and clinical applications, *3 Biotech* 5 (2) (2015) 129–151.
- [54] A. Salminen, M. Lehtonen, T. Suuronen, K. Kaarniranta, J. Huuskonen, Terpenoids: natural inhibitors of NF- κ B signaling with anti-inflammatory and anticancer potential, *Cell Molec. Life Sci.* 65 (19) (2008) 2979–2999.
- [55] M.T. Islam, Diterpenes and their derivatives as potential anticancer agents, *Phytother. Res.* 31 (5) (2017) 691–712.
- [56] V. Khwaza, O.O. Oyediji, B.A. Aderibigbe, Antiviral activities of oleanolic acid and its analogues, *Molecules* 23 (9) (2018) 2300.
- [57] X. Liu, J. Cao, G. Huang, Q. Zhao, J. Shen, Biological activities of artemisinin derivatives beyond malaria, *Curr. Top. Med. Chem.* 19 (3) (2019) 205–222.
- [58] S.R. Chen, Y. Dai, J. Zhao, L. Lin, Y. Wang, Y. Wang, A mechanistic overview of triptolide and celastrol, natural products from *Tripterygium wilfordii* Hook F, *Front. Pharmacol.* 9 (2018) 104.
- [59] J. Xu, E.A. Wold, Y. Ding, Q. Shen, J. Zhou, Therapeutic potential of oridonin and its analogs: from anticancer and antiinflammation to neuroprotection, *Molecules* 23 (2) (2018).
- [60] Q.Q. Liu, H.L. Wang, K. Chen, S.B. Wang, Y. Xu, Q. Ye, Y.W. Sun, Oridonin derivative ameliorates experimental colitis by inhibiting activated T-cells and translocation of nuclear factor-kappa B, *J. Dig. Dis.* 17 (2) (2016) 104–112.
- [61] V. Kishore, N.S. Yarla, A. Bishayee, S. Putta, R. Malla, N.R. Neelapu, S. Challa, S. Das, Y. Shiralgi, G. Hegde, B.L. Dhananjaya, Multi-targeting andrographolide and its natural analogs as potential therapeutic agents, *Curr. Top. Med. Chem.* 17 (8) (2017) 845–857.
- [62] S.H. Venkatesha, S. Dudics, B. Astry, K.D. Moudgil, Control of autoimmune inflammation by celastrol, a natural triterpenoid, *Pathog. Dis.* 74 (6) (2016).
- [63] Q.T.N. Tran, W.S.F. Wong, C.L.L. Chai, Labdane diterpenoids as potential anti-inflammatory agents, *Pharmacol. Res.* 124 (2017) 43–63.
- [64] B. de las Heras, B. Rodriguez, L. Bosca, A.M. Villar, Terpenoids: sources, structure elucidation and therapeutic potential in inflammation, *Curr. Top. Med. Chem.* 3 (2) (2003) 171–185.
- [65] B. de las Heras, S. Hortelano, Molecular basis of the anti-inflammatory effects of terpenoids, *Inflamm. Allergy Drug Targets* 8(1) (2009) 28–39.
- [66] C. Juliana, T. Fernandes-Alnemri, J. Wu, P. Datta, L. Solorzano, J.W. Yu, R. Meng, A.A. Quong, E. Latz, C.P. Scott, E.S. Alnemri, Anti-inflammatory compounds parthenolide and Bay 11–7082 are direct inhibitors of the inflammasome, *J. Biol. Chem.* 285 (13) (2010) 9792–9802.
- [67] X.C. Pan, Y. Liu, Y.Y. Cen, Y.L. Xiong, J.M. Li, Y.Y. Ding, Y.F. Tong, T. Liu, X.H. Chen, H.G. Zhang, Dual role of triptolide in interrupting the NLRP3 inflammasome pathway to attenuate cardiac fibrosis, *Int. J. Mol. Sci.* 20 (2) (2019).
- [68] R. Li, K. Lu, Y. Wang, M. Chen, F. Zhang, H. Shen, D. Yao, K. Gong, Z. Zhang, Triptolide attenuates pressure overload-induced myocardial remodeling in mice via the inhibition of NLRP3 inflammasome expression, *Biochem. Biophys. Res. Commun.* 485 (1) (2017) 69–75.
- [69] L. He, X. Peng, G. Liu, C. Tang, H. Liu, F. Liu, H. Zhou, Y. Peng, Anti-inflammatory effects of triptolide on IgA nephropathy in rats, *Immunopharmacol. Immunotoxicol.* 37 (5) (2015) 421–427.
- [70] H. He, H. Jiang, Y. Chen, J. Ye, A. Wang, C. Wang, Q. Liu, G. Liang, X. Deng, W. Jiang, R. Zhou, Oridonin is a covalent NLRP3 inhibitor with strong anti-inflammatory activity, *Nat. Commun.* 9 (1) (2018) 2550.
- [71] H. Yang, H. Lv, H. Li, X. Ci, L. Peng, Oridonin protects LPS-induced acute lung injury by modulating Nrf2-mediated oxidative stress and Nrf2-independent NLRP3 and NF- κ B pathways, *Cell Commun. Signal.* 17 (1) (2019) 62.
- [72] D. Cabrera, A. Wree, D. Povero, N. Solis, A. Hernandez, M. Pizarro, H. Moshage, J. Torres, A.E. Feldstein, C. Cabello-Verrugio, E. Brandan, F. Barrera, J.P. Arab, M. Arrese, Andrographolide ameliorates inflammation and fibrogenesis and attenuates inflammasome activation in experimental non-alcoholic steatohepatitis, *Sci. Rep.* 7 (1) (2017) 3491.
- [73] S. Peng, J. Gao, W. Liu, C. Jiang, X. Yang, Y. Sun, W. Guo, Q. Xu, Andrographolide ameliorates OVA-induced lung injury in mice by suppressing ROS-mediated NF- κ B signaling and NLRP3 inflammasome activation, *Oncotarget* 7 (49) (2016) 80262–80274.
- [74] W. Guo, Y. Sun, W. Liu, X. Wu, L. Guo, P. Cai, X. Wu, X. Wu, Y. Shen, Y. Shu, Y. Gu, Q. Xu, Small molecule-driven mitophagy-mediated NLRP3 inflammasome inhibition is responsible for the prevention of colitis-associated cancer, *Autophagy* 10 (6) (2014) 972–985.
- [75] X. Li, T. Wang, D. Zhang, H. Li, H. Shen, X. Ding, G. Chen, Andrographolide ameliorates intracerebral hemorrhage induced secondary brain injury by inhibiting neuroinflammation induction, *Neuropharmacology* 141 (2018) 305–315.
- [76] X. Yu, Q. Zhao, X. Zhang, H. Zhang, Y. Liu, X. Wu, M. Li, X. Li, J. Zhang, X. Ruan, H. Zhang, Celastrol ameliorates inflammation through inhibition of NLRP3 inflammasome activation, *Oncotarget* 8 (40) (2017) 67300–67314.
- [77] M.E. Shaker, S.A. Ashamalla, M.E. Houssem, Celastrol ameliorates murine colitis via modulating oxidative stress, inflammatory cytokines and intestinal homeostasis, *Chem. Biol. Interact.* 210 (2014) 26–33.
- [78] W. Xin, Q. Wang, D. Zhang, C. Wang, A new mechanism of inhibition of IL-1 β secretion by celastrol through the NLRP3 inflammasome pathway, *Eur. J. Pharmacol.* 814 (2017) 240–247.
- [79] X. Sang, Y. Chen, W. Chen, J. Xie, G. Meng, J. Zhong, T. Li, A. Lu, Celastrol specifically inhibits the activation of NLRP3 inflammasome, *Sci. China Life Sci.* 61 (3) (2018) 355–357.
- [80] S.X. Yu, C.T. Du, W. Chen, Q.Q. Lei, N. Li, S. Qi, X.J. Zhang, G.Q. Hu, X.M. Deng, W.Y. Han, Y.J. Yang, Genipin inhibits NLRP3 and NLRCA4 inflammasome activation via autophagy suppression, *Sci. Rep.* 5 (2015) 17935.
- [81] V. Rajanbabu, H. Galam, J. Fukumoto, J. Enciso, P. Tadikonda, T.N. Lane, S. Bandyopadhyay, P.T. Parthasarathy, Y. Cho, S.H. Cho, Y.C. Lee, R.F. Lockey, N. Kolliputi, Genipin suppresses NLRP3 inflammasome activation through uncoupling protein-2, *Cell. Immunol.* 297 (1) (2015) 40–45.
- [82] M.J. Seo, J.M. Hong, S.J. Kim, S.M. Lee, Genipin protects d-galactosamine and lipopolysaccharide-induced hepatic injury through suppression of the necroptosis-mediated inflammasome signaling, *Eur. J. Pharmacol.* 812 (2017) 128–137.
- [83] Y. Yang, H. Wang, M. Kouadir, H. Song, F. Shi, Recent advances in the mechanisms of NLRP3 inflammasome activation and its inhibitors, *Cell Death Dis.* 10 (2) (2019) 128.
- [84] N. Irrera, M. Vaccaro, A. Bitto, G. Pallio, G. Pizzino, M. Lentini, V. Arcoraci, L. Minutoli, M. Scuruchi, G. Cutroneo, G.P. Anastasi, R. Ettari, F. Squadrito, D. Altavilla, BAY 11-7082 inhibits the NF- κ B and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis, *Clin. Sci. (Lond.)* 131 (6) (2017) 487–498.
- [85] R.C. Coll, A.A. Robertson, J.J. Chae, S.C. Higgins, R. Munoz-Planillo, M.C. Inerra, I. Vetter, L.S. Dungan, B.G. Monks, A. Stutz, D.E. Croker, M.S. Butler, M. Hancock, C.E. Sutton, G. Nunez, E. Latz, D.L. Kastner, K.H. Mills, S.L. Masters, K. Schroder, M.A. Cooper, L.A. O'Neill, A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases, *Nat. Med.* 21 (3) (2015) 248–255.
- [86] A.P. Perera, R. Fernando, T. Shinde, R. Gundamaraju, B. Southam, S.S. Sohal, A.A.B. Robertson, K. Schroder, D. Kunde, R. Eri, MCC950, a specific small molecule inhibitor of NLRP3 inflammasome attenuates colonic inflammation in spontaneous colitis mice, *Sci. Rep.* 8 (1) (2018) 8618.
- [87] A. Tapia-Abellan, D. Angosto-Bazarrá, H. Martínez-Banaolocha, C. de Torre-Minguela, J.P. Ceron-Carrasco, H. Perez-Sanchez, J.I. Arostegui, P. Pelegrin, MCC950 closes the active conformation of NLRP3 to an inactive state, *Nat. Chem.*

- Biol. 15 (6) (2019) 560–564.
- [88] Y. Huang, H. Jiang, Y. Chen, X. Wang, Y. Yang, J. Tao, X. Deng, G. Liang, H. Zhang, W. Jiang, R. Zhou, Tranilast directly targets NLRP3 to treat inflammasome-driven diseases, *EMBO Mol. Med.* 10 (4) (2018).
- [89] H. Jiang, H. He, Y. Chen, W. Huang, J. Cheng, J. Ye, A. Wang, J. Tao, C. Wang, Q. Liu, T. Jin, W. Jiang, X. Deng, R. Zhou, Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders, *J. Exp. Med.* 214 (11) (2017) 3219–3238.
- [90] C. Marchetti, B. Swartzwelter, F. Gamboni, C.P. Neff, K. Richter, T. Azam, S. Carta, I. Tengedal, T. Nemkov, A. D'Alessandro, C. Henry, G.S. Jones, S.A. Goodrich, J.P. St Laurent, T.M. Jones, C.L. Scribner, R.B. Barrow, R.D. Altman, D.B. Skouras, M. Gattorno, V. Grau, S. Janciauskiene, A. Rubartelli, L.A.B. Joosten, C.A. Dinarello, OLT1177, a beta-sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation, *Proc. Natl. Acad. Sci. U.S.A.* 115 (7) (2018) E1530-e1539.
- [91] C. Marchetti, B. Swartzwelter, M.I. Koenders, T. Azam, I.W. Tengedal, N. Powers, D.M. de Graaf, C.A. Dinarello, L.A.B. Joosten, NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis, *Arthritis Res. Ther.* 20 (1) (2018) 169.